While blood eosinophil count is the biomarker used in clinical practice to enable selective use of inhaled corticosteroids (ICS) in COPD, there is a complex interacting network involving the microbiome, airway inflammation and ICS that decides the clinical outcome in individuals.
Read the pick of the week | Submit your manuscript to the European Respiratory Review
Friday 3 November 2023
European Respiratory Review: pick of the week
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment